Premier Alternatives

Pheast Therapeutics

Redwood City, CA · Founded 2021 · Privately Held (backing)

Provider of immuno-oncology therapies intended to activate the innate immune system to fight cancer. Pheast Therapeutics is based in Redwood City, CA and was founded in 2021. It was valued at $155 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $101 million across 2 recorded rounds; the latest was a $24.6 million early-stage round in Oct 2025.

PMV mark · valuation
$154.6M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$100.6M
Last round
Early Stage VC
Oct 2025

Pheast Therapeutics key facts

as of Oct 2026
  • Provider of immuno-oncology therapies intended to activate the innate immune system to fight cancer.
  • Pheast Therapeutics is valued at approximately $154.6M as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $100.6M across 2 recorded rounds; the latest was Early Stage VC ($24.6M) in Oct 2025.
  • Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Catalio Capital Management, Rsquared.
  • Pheast Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Apr 2025 ($75.3M sold to 7 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$154.6M

Valued at $154.6M at its early-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Pheast Therapeutics with a free account
  • ·Watch Pheast Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Pheast Therapeutics funding rounds

2 rounds
Oct 2025Early Stage VC$24.6MSEC filing▮
Jan 2022Later Stage VC$75.3MSEC filing▮
Full funding history →

Pheast Therapeutics valuation

Pheast Therapeutics was valued at $155 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Pheast Therapeutics raised?

Pheast Therapeutics has raised $101 million across 2 recorded rounds since 2022. The largest was a $75.3 million later-stage round in Jan 2022; the most recent was a $24.6 million early-stage round in Oct 2025.

Pheast Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in Apr 2025 ($75.3 million sold to 7 investors).

Pheast Therapeutics investors

4 investors are on record for Pheast Therapeutics, including Alexandria Venture Investments, ARCH Venture Partners, Catalio Capital Management and Rsquared. The early-stage round in Oct 2025 drew 7 investors.

About Pheast Therapeutics

Provider of immuno-oncology therapies intended to activate the innate immune system to fight cancer. The company offers an anti-CD24 macrophage checkpoint inhibitor engineered to induce macrophages to engulf and destroy cancer cells, alongside additional therapies for aggressive cancers, enabling patients with hard-to-treat tumors to benefit from targeted immune activation.

Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2021
Employees
33
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.